With regard to baseline disease characteristics (Table 2), patients on combination therapy were more likely to have concomitant PsA (57% vs 36%, P<0.001). However, no other characteristics of their psoriatic disease differed significantly between the groups.
There were several notable differences in PROs (Table 3). The combination group experienced more overall fatigue, missed more hours from work, and had more problems performing activities of daily living. Table 4 details the treatment status and histories at enrollment for patients initiating biologic combination and mono-therapy. Combination therapy patients were much less likely to be naïve to non-biologic systemic medications; in other words, nearly all patients had tried a traditional systemic agent compared to only half of the monotherapy group. No significant statistical difference was observed in treatment history with biologic drugs, including number of biologics tried and combination naivety.
There were several notable differences in PROs (Table 3). The combination group experienced more overall fatigue, missed more hours from work, and had more problems performing activities of daily living. Table 4 details the treatment status and histories at enrollment for patients initiating biologic combination and mono-therapy. Combination therapy patients were much less likely to be naïve to non-biologic systemic medications; in other words, nearly all patients had tried a traditional systemic agent compared to only half of the monotherapy group. No significant statistical difference was observed in treatment history with biologic drugs, including number of biologics tried and combination naivety.
